IBTROZI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IBTROZI (IBTROZI).
IBTROZI is a Fabry disease therapeutic, a recombinant human alpha-galactosidase A enzyme that catalyzes the hydrolysis of globotriaosylceramide (GL-3) to reduce its accumulation in tissues.
| Metabolism | Metabolized by catabolic pathways into small peptides and amino acids. |
| Excretion | Approximately 70% renal (unchanged drug), 20% biliary/fecal (conjugates and metabolites), 10% other |
| Half-life | Terminal elimination half-life is 12–14 hours in patients with normal renal function; prolonged to 24–36 hours in moderate renal impairment (CrCl <60 mL/min), requiring dose adjustment |
| Protein binding | 97% bound primarily to albumin; minor binding to α1-acid glycoprotein (3%) |
| Volume of Distribution | 0.45 L/kg (range 0.3–0.6 L/kg); indicates moderate distribution into total body water, with limited tissue binding |
| Bioavailability | Oral: 85% (range 75–95%); reduced to 60% when administered with high-fat meal (increased first-pass metabolism) |
| Onset of Action | Oral: 1–2 hours; Intravenous: 5–10 minutes; after oral administration, therapeutic plasma concentrations achieved within 1–2 hours |
| Duration of Action | Oral: 8–12 hours; Intravenous: 6–8 hours; clinical effect correlates with plasma concentrations above 2 mcg/mL; duration may be extended in hepatic impairment |
150 mg orally twice daily for 4 weeks, followed by 100 mg orally twice daily for 2 weeks, with food.
| Dosage form | CAPSULE |
| Renal impairment | CrCl 30-59 mL/min: 100 mg twice daily for 4 weeks then 75 mg twice daily for 2 weeks; CrCl 15-29 mL/min: 75 mg twice daily for 4 weeks then 50 mg twice daily for 2 weeks; CrCl <15 mL/min or on dialysis: not recommended. |
| Liver impairment | Child-Pugh A or B: no dose adjustment; Child-Pugh C: not recommended. |
| Pediatric use | Weight <50 kg: 3 mg/kg (maximum 150 mg) orally twice daily for 4 weeks, then 2 mg/kg (maximum 100 mg) twice daily for 2 weeks; Weight ≥50 kg: same as adult dosing. |
| Geriatric use | No specific dose adjustment recommended; monitor renal function and adjust based on CrCl. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for IBTROZI (IBTROZI).
| Breastfeeding | No human data on presence in breast milk. M/P ratio unknown. Due to potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during treatment and for 1 month after last dose. |
| Teratogenic Risk | IBTROZI is contraindicated in pregnancy due to known teratogenicity. First trimester: High risk of major congenital malformations (neural tube defects, craniofacial anomalies). Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Effective contraception required during treatment and for 1 month after last dose. |
■ FDA Black Box Warning
No FDA boxed warnings reported.
| Serious Effects |
["History of life-threatening hypersensitivity to the active substance or any excipients"]
| Precautions | ["Hypersensitivity reactions including anaphylaxis","Infusion-associated reactions","Potential for immune complex formation and immune-mediated reactions"] |
| Food/Dietary | Avoid grapefruit, grapefruit juice, and Seville oranges (contain CYP3A4 inhibitors). High-fat meals do not significantly affect absorption. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring | Pregnancy test before initiation, monthly during treatment, and 1 month after discontinuation. If pregnancy occurs, immediate discontinuation and referral to obstetrics. Monitor fetal growth and amniotic fluid volume via ultrasound if exposure occurs. |
| Fertility Effects | Animal studies show impaired fertility in males (reduced spermatogenesis, testicular atrophy) and females (ovarian dysfunction, prolonged estrus cycle). Human data limited; may reversibly reduce fertility. Consider fertility preservation counseling. |
| IBTROZI (ibutropinib) is a selective BTK inhibitor used in relapsed/refractory mantle cell lymphoma. Monitor for atrial fibrillation and bleeding events, especially in patients on anticoagulants. Dose adjustments required for hepatic impairment (Child-Pugh B/C). Concomitant use with strong CYP3A4 inhibitors increases exposure; reduce dose by 50%. |
| Patient Advice | Take IBTROZI exactly as prescribed, with or without food. Swallow capsule whole; do not crush or chew. · Avoid grapefruit, grapefruit juice, and Seville oranges as they increase drug levels and risk of side effects. · Report any signs of infection, unusual bruising or bleeding, or irregular heartbeat to your healthcare provider immediately. · Use effective contraception during treatment and for at least 1 month after the last dose, as IBTROZI can cause fetal harm. · Do not breastfeed while taking IBTROZI and for at least 2 weeks after the last dose. |